Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review
- PMID: 33590943
- DOI: 10.1002/ptr.7046
Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review
Abstract
Metabolic syndrome is known as a group of metabolic abnormalities with features including central obesity, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and hypertension as well as low level of high-density lipoprotein (HDL)-cholesterol. Previous studies showed the ameliorating effects of Scutellaria baicalensis on metabolic syndrome parameters, including antidiabetic, anti-hyperlipidemic, anti-obesity, and antihypertensive. In this review, we deeply and mechanistically evaluated different studies on the effect of S. baicalensis and its two major bioactive constituents, baicalin, and baicalein, on the critical components of metabolic syndrome, including diabetes, hyperlipidemia, obesity, hypertension, and atherosclerosis. Scientific databases, including PubMed, Scopus, and Google Scholar were searched in the English language until the end of June 2020. Accordingly, S. baicalensis, and its two major bioactive constituents, baicalin and baicalein, represent promising effects on the control of metabolic syndrome and its related disorders such as obesity, hyperlipidemia, atherosclerosis, diabetes, and their following complications. In summary, our findings show that S. baicalensis and its active constituents, baicalin and baicalein, by activation and upregulation of AMPK and PPAR-γ as the main signaling in the hemostasis of glucose and lipid metabolisms may be favorable candidates for the prevention and treatment of the metabolic syndrome.
Keywords: Scutellaria baicalensis; diabetes; dyslipidemia; metabolic syndrome; obesity.
© 2021 John Wiley & Sons, Ltd.
Similar articles
-
Baicalin and its aglycone: a novel approach for treatment of metabolic disorders.Pharmacol Rep. 2020 Feb;72(1):13-23. doi: 10.1007/s43440-019-00024-x. Epub 2020 Jan 8. Pharmacol Rep. 2020. PMID: 32016847
-
Research progress of active ingredients of Scutellaria baicalensis in the treatment of type 2 diabetes and its complications.Biomed Pharmacother. 2022 Apr;148:112690. doi: 10.1016/j.biopha.2022.112690. Epub 2022 Feb 11. Biomed Pharmacother. 2022. PMID: 35158145 Review.
-
Flavone-catalyzed apoptosis in Scutellaria baicalensis.Phytochemistry. 2011 Jun;72(8):752-60. doi: 10.1016/j.phytochem.2011.02.009. Epub 2011 Mar 4. Phytochemistry. 2011. PMID: 21377703
-
Scutellaria baicalensis and its constituents baicalin and baicalein as antidotes or protective agents against chemical toxicities: a comprehensive review.Naunyn Schmiedebergs Arch Pharmacol. 2022 Nov;395(11):1297-1329. doi: 10.1007/s00210-022-02258-8. Epub 2022 Jun 9. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35676380 Review.
-
The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters.J Pharm Sci. 2013 Nov;102(11):4205-11. doi: 10.1002/jps.23727. Epub 2013 Sep 9. J Pharm Sci. 2013. PMID: 24018852
Cited by
-
Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin.Pharmaceutics. 2022 Oct 9;14(10):2141. doi: 10.3390/pharmaceutics14102141. Pharmaceutics. 2022. PMID: 36297576 Free PMC article.
-
Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review.Evid Based Complement Alternat Med. 2021 Nov 29;2021:8402517. doi: 10.1155/2021/8402517. eCollection 2021. Evid Based Complement Alternat Med. 2021. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 13;2023:9796340. doi: 10.1155/2023/9796340. PMID: 34880922 Free PMC article. Retracted. Review.
-
Interplay between Phytochemicals and the Colonic Microbiota.Nutrients. 2023 Apr 20;15(8):1989. doi: 10.3390/nu15081989. Nutrients. 2023. PMID: 37111207 Free PMC article. Review.
-
Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals.Cell Prolif. 2025 Jul;58(7):e70012. doi: 10.1111/cpr.70012. Epub 2025 Mar 5. Cell Prolif. 2025. PMID: 40045164 Free PMC article. Review.
-
Several major herb pairs containing Coptidis rhizoma: a review of key traditional uses, constituents and compatibility effects.Front Pharmacol. 2024 Jun 25;15:1399460. doi: 10.3389/fphar.2024.1399460. eCollection 2024. Front Pharmacol. 2024. PMID: 38983920 Free PMC article. Review.
References
REFERENCES
-
- Ahluwalia, M., & Bangalore, S. (2017). Management of hypertension in 2017: Targets and therapies. Current Opinion in Cardiology, 32(4), 413-421.
-
- Akaberi, M., & Hosseinzadeh, H. (2016). Grapes (Vitis vinifera) as a potential candidate for the therapy of the metabolic syndrome. Phytotherapy Research, 30(4), 540-556.
-
- Akbar, D. H., & Kawther, A. H. (2006). Non-alcoholic fatty liver disease and metabolic syndrome: What we know and what we don't know. Medical Science Monitor, 12(1), Ra23-Ra26.
-
- Baradaran Rahimi, V., Ghadiri, M., Ramezani, M., & Askari, V. R. (2020). Antiinflammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studies. Phytotherapy Research, 34(4), 685-720.
-
- Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012). The interaction of hepatic lipid and glucose metabolism in liver diseases. Journal of Hepatology, 56(4), 952-964.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical